Skip to main content
SpringerLink
Log in

Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates ofPseudomonas aeruginosa

  • New Antimicrobial Agents
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The in vitro activity of a new parenteral cephalosporin cefepime (BMY 28142) was compared with that of ceftazidime, cefotaxime, piperacillin, imipenem, gentamicin, amikacin and ciprofloxacin against 173 recent multiresistantPseudomonas aeruginosa isolates of nosocomial origin using an agar dilution technique with an inoculum of 104 CFU per spot. The activity of cefepime was comparable to that of ceftazidime, superior to that of cefotaxime, piperacillin, gentamicin and amikacin, but inferior to that of imipenem and ciprofloxacin. Cross-resistance ofPseudomonas aeruginosa to ceftazidime and cefepime occurred in nearly 50% of the cefepime resistant strains and 61.5% of the ceftazidime resistant strains respectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Khan, N. J., Bihl, J. A., Schell, R. F., LeFrock, J. L., Weber, S. J.: Antimicrobial activities of BMY-28142, cefoperazone and cefpiramide compared with those of other cephalosporins. Antimicrobial Agents and Chemotherapy 1984, 26: 585–590.

    Google Scholar 

  2. Kessler, R. E., Bies, M., Buck, R. E., Chisholm, D. R., Pursiano, T. A., Tsai, Y. H., Misiek, M., Price, K. E., Leitner, F.: Comparison of a new cephalosporin, BMY-28142, with other broad-spectrumβ-lactam antibiotics. Antimicrobial Agents and Chemotherapy 1985, 27: 207–216.

    Google Scholar 

  3. Tsuji, A., Maniatis, A., Bertram, M. A., Young, L. S.: In vitro activity of BMY-28142 in comparison with those of otherβ-lactam antimicrobial agents. Antimicrobial Agents and Chemotherapy 1985, 27: 515–519.

    Google Scholar 

  4. Fuchs, P. C., Jones, R. N., Barry, A. L., Thornsberry, C.: Evaluation of in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrobial Agents and Chemotherapy 1985, 27: 679–682.

    Google Scholar 

  5. Conrad, D. A., Scribner, R. K., Weber, A. H., Marks, M. I.: In vitro activity of BMY-28142 against pediatric pathogens including isolates from cystic fibrosis sputum. Antimicrobial Agents and Chemotherapy 1985, 28: 58–63.

    Google Scholar 

  6. Giamarellou, H., Sahin, A., Chryssouli, Z.: Comparative in vitro evaluation of BMY-28142, a new broad-spectrum cephalosporin, versus otherβ-lactams against multiresistant gram-negative isolates. Drugs under Experimental and Clinical Research 1987, 13: 149–153.

    Google Scholar 

  7. Fung-Tomc, J., Huczko, E., Pearce, M., Kessler, R. E.: Frequency of in vitro resistance ofPseudomonas aeruginosa to cefepime, ceftazidime and cefotaxime. Antimicrobial Agents and Chemotherapy 1988, 32: 1443–1445.

    Google Scholar 

  8. Sanders, C. C., Sanders, W. E.: Type Iβ-lactamases of gram-negative bacteria: interactions withβ-lactam antibiotics. Journal of Infectious Diseases 1986, 154: 792–800.

    Google Scholar 

  9. Stratton, C. W., Tansk, F.: Synergistic resistance mechanisms inPseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 1987, 19: 413–416.

    Google Scholar 

  10. Phelps, D. J., Carlton, D. D., Farrel, C. A., Kessler, R. E.: Affinity of cephalosporins forβ-lactamases as a factor in antibacterial efficacy. Antimicrobial Agents and Chemotherapy 1986, 29: 845–848.

    Google Scholar 

  11. Vuge, A., Pijck, J.: In vitro activity of BMY-28142 a new extended spectrum cephalosporin. Antimicrobial Agents and Chemotherapy 1985, 27: 574–577.

    Google Scholar 

  12. Giamarellou, H., Touliatou, K., Koratzanis, G., Petrikkos, G., Kanellakopoulou, K., Lelekis, M., Pagona, A., Tsagarakis, J., Symeonides, J., Falagas, M.: Nosocomial consequences of antibiotic usage. Scandinavian Journal of Infectious Diseases 1986, Supplement 49: 182–188.

    Google Scholar 

  13. Täuber, M. G., Hackbarth, C. J., Scott, K. G., Rusnak, M. G., Sande, M. E.: New cephalosporins cefotaxime, cefpimizole, BMY 28142 and HR 810 in experimental meningitis in rabbits. Antimicrobial Agents and Chemotherapy 1985, 27: 340–342.

    Google Scholar 

  14. Kim, K. S., Bayer, A. S.: Efficacy of BMY-28142 in experimental bacteremia and meningitis caused byEscherichia coli and group B streptococci. Antimicrobial Agents and Chemotherapy 1985, 28: 51–54.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Propedeutic Medicine, Athens University School of Medicine, Laiko, General Hospital, GR 115 27, Athens, Greece

    D. Voutsinas, T. Mavroudis, A. Avlamis & H. Giamarellou

Authors
  1. D. Voutsinas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Mavroudis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Avlamis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Giamarellou
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Voutsinas, D., Mavroudis, T., Avlamis, A. et al. Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates ofPseudomonas aeruginosa . Eur. J. Clin. Microbiol. Infect. Dis. 8, 917–919 (1989). https://doi.org/10.1007/BF01963783

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01963783

Keywords

Search

Navigation